Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Startseite Know-how Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

Efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) under field conditions

The aim of this study was to confirm the efficacy of a commercial vaccine containing Histophilus somni and Mannheimia haemolytica leukotoxoid (HIPRABOVIS® SOMNI/Lkt) in reducing clinical respiratory signs and the number of concomitant treatments under field conditions.

Über diesen Artikel

Datum

06.09.2016

Zusammenfassung

Vaccination with the commercial vaccine HIPRABOVIS® SOMNI/Lkt reduced the number of animals showing clinical respiratory signs and the number of concomitant treatments used during the first three months after arrival at the fattening farm.

Teilen